New insights on pneumococcal disease: What we have learned over the past decade

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2000, significant reductions in the rate of invasive pneumococcal diseases (IPDs) and mucosal infections caused by vaccine-specific serotypes have been observed in the targeted population (children aged <5 years). IPD rates have also decreased in adults aged ≥65 years, suggesting the extension of vaccine protection to the unimmunized population. A concomitant decline has been noted in antibiotic-resistant Streptococcus pneumoniae isolates. The incidence of vaccine-serotype IPD varies widely in geographically disparate regions, indicating that serotype coverage alone may not accurately predict the impact of proposed pneumococcal conjugate vaccines with additional serotypes.

Original languageEnglish
Pages (from-to)C3-C5
JournalVaccine
Volume27
Issue numberSUPPL. 3
DOIs
StatePublished - 21 Aug 2009
Externally publishedYes

Keywords

  • Effectiveness
  • PCV7
  • Pneumococcal disease

Fingerprint

Dive into the research topics of 'New insights on pneumococcal disease: What we have learned over the past decade'. Together they form a unique fingerprint.

Cite this